BCR and B-cell chronic lymphocytic leukemia: The importance of cell-extrinsic triggering for CLL pathophysiology was recently also highlighted by the clinical efficacy of novel drugs targeting microenvironmental interactions through the inhibition of BCR signaling, e.g., Acalabrutinib and Duvelisib (57).